abiraterone-acetate and Paralysis

Prostate cancer (PC) is the most common type of neoplasm in men and the fourth leading cause of mortality in Brazil. The prostate cancer refractory metastatic castration can be treated with abiraterone acetate (AA).. Its use has been associated with increased survival. However, there are also side effects associated with the use of this drug, such as severe electrolyte disturbances.. The objective is to report the clinical case of a patient with castration-resistant metastatic prostate cancer who developed ascending flaccid paralysis secondary to severe hypokalemia, probably due to hyperaldosteronism secondary to the use of Abiraterone Acetate, despite the use of Prednisone.

Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Hypokalemia; Male; Paralysis; Prednisone; Prostatic Neoplasms, Castration-Resistant